Trial Profile

Phase I/IIa Systemic Gene Delivery Clinical Trial of scAAV9.U7.ACCA for Exon 2 Duplication-Associated Duchenne Muscular Dystrophy

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AT 702 (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions

Most Recent Events

01 Aug 2022 Status changed from active, no longer recruiting to discontinued, according to an Astellas Pharma media release.
25 Nov 2021 Planned End Date changed from 15 Jan 2025 to 19 Nov 2025.
25 Nov 2021 Planned primary completion date changed from 15 Jan 2023 to 19 Nov 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com